<DOC>
	<DOC>NCT00621244</DOC>
	<brief_summary>This study will evaluate safety, tolerability, pharmacokinetics and preliminary anti-leukemic or anti-tumor activity of LBH589B in adult patients with advanced hematological malignancies</brief_summary>
	<brief_title>A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Inclusion criteria: Adult patients (≥18 years old) with advanced hematological malignancies who have relapsed after or are refractory to standard therapy, or for which no standard therapy exists; or, are considered inappropriate candidates for standard therapy World Health Organization (WHO) performance status ≤ 2 Patients must meet protocolspecified hematologic and nonhematologic laboratory values Patients must have adequate liver and renal function Exclusion criteria: Concurrent brain metastases or leukemic infiltration of the cerebrospinal fluid Peripheral neuropathy ≥ CTCAE grade 2 Unresolved diarrhea ≥ CTCAE grade 2 Concurrent severe and/or uncontrolled medical conditions which may compromise participation in the study, including impaired heart function or clinically significant heart disease, and impaired gastrointestinal function or disease that may significantly alter aborption of LBH589 Female patients who are pregnant or breast feeding Patients not willing to use an effective method of birth control Patients taking medications specified by the protocol as prohibited for administration in combination with LBH589 Patients with another primary malignancy that currently requires active intervention or is currently clinically significant Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>HDAC inhibitor</keyword>
	<keyword>Oral</keyword>
	<keyword>LBH589</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Multiple myeloma</keyword>
</DOC>